Evidence map›Paper›PMID 39892089›Full record

Trial reportDrug and alcohol dependence2025

Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial.

Matisyahu Shulman, Tse-Hwei Choo, Kaitlyn Ohrtman, Martina Pavlicova, John Rotrosen, Edward V Nunes

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matisyahu ShulmanNew York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10034, USA; Department of Psychiatry, Columbia University Medical Center, 630 W168th St, New York, NY 10032, USA. Electronic address: matisyahu.shulman@nyspi.columbia.edu.
Tse-Hwei ChooNew York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10034, USA.
Kaitlyn OhrtmanNew York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10034, USA; Department of Psychiatry, Columbia University Medical Center, 630 W168th St, New York, NY 10032, USA.
Martina PavlicovaDepartment of Biostatistics, Mailman School of Public Health, Columbia University, 722 Riverside Dr, New York, NY 10032, USA.
John RotrosenDepartment of Psychiatry, New York University School of Medicine, 550 First Ave, New York, NY 10016, USA.
Edward V NunesNew York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10034, USA; Department of Psychiatry, Columbia University Medical Center, 630 W168th St, New York, NY 10032, USA.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Translational Clinical Research Fellowship on Substance Use DisordersT32DA007294 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Frances Rudnick Levin, Diana M Martinez · 1993 to 2026
$9.3M
NIDA NIH HHS T32 DA007294NIDA NIH HHS UG1 DA013035
6 · The paper itself

Abstract

aimsCannabis use is highly prevalent in patients seeking treatment for opioid use disorder. Studies have shown mixed results on the association between cannabis use and opioid use as well as the impact of MOUD on cannabis use. The current study aims to investigate the effects of buprenorphine versus naltrexone on cannabis use outcomes in treatment seeking individuals with Opioid Use Disorder (OUD).

methodsThe current study was based on data from the CTN-0051 X:BOT trial, which compared the time to return to significant opioid use survival outcomes of two treatment seeking groups, one receiving Extended-Release Naltrexone (XR-naltrexone) (N = 283) versus another receiving Buprenorphine-Naloxone (N = 287) for OUD. A mixed-effects logistic regression model including treatment assignment (buprenorphine-naloxone vs XR-naltrexone), time, and a time by treatment interaction was run on the sample with the odds of cannabis use as the outcome, as well as two cross-lagged mediation models to explore the prospective mediation of cannabis use on opioid use outcomes (and opioid use on cannabis use outcomes) by treatment assignment during the trial.

resultsThere was a significant effect of buprenorphine treatment on reduced cannabis use. Participants receiving buprenorphine treatment were 39 % less likely to use cannabis than those receiving naltrexone over all the timepoints (p = .0499). No significant mediation was found between treatment assignment and opioid use on cannabis use outcomes or between treatment assignment and cannabis use on opioid use outcomes in this trial.

conclusionParticipants in this trial receiving buprenorphine treatment for OUD used less cannabis than those receiving naltrexone treatment.

Indexed as

BuprenorphineBuprenorphine, Naloxone Drug CombinationMarijuana UseNaltrexoneNarcotic AntagonistsOpioid-Related DisordersAdultFemaleHumansMaleMiddle AgedOpiate Substitution TreatmentTreatment OutcomeBuprenorphineBuprenorphine, Naloxone Drug CombinationNaltrexoneNarcotic AntagonistsBuprenorphineCannabis use disorderNaltrexoneOpioid use disorderTimeline follow backTreatment effect

Identifiers

PMID39892089
PMCPMC11832313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.